Guidant Accepts Yet Another J&J Bid As Takeover War Escalates
This article was originally published in The Gray Sheet
Executive Summary
Guidant accepted an increased takeover bid by Johnson & Johnson late Jan. 13, leaving Boston Scientific to once again weigh whether to continue its bidding war with J&J
You may also be interested in...
Guidant Catches Boston Scientific’s “Hail Mary” Offer; J&J Weighs Options
Guidant's board of directors determined Jan. 17 that Boston Scientific's latest acquisition offer of $80 per share, or $27.2 bil., is superior to its previous agreement with Johnson & Johnson for $71 per share
Guidant Catches Boston Scientific’s “Hail Mary” Offer; J&J Weighs Options
Guidant's board of directors determined Jan. 17 that Boston Scientific's latest acquisition offer of $80 per share, or $27.2 bil., is superior to its previous agreement with Johnson & Johnson for $71 per share
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC